Biogen Early Access Programs
Product by Biogen
Providing pathways to investigational medicines for patients with serious unmet medical needs.
Biogen Early Access Programs provide a pathway for patients with serious or life-threatening conditions to access investigational drugs when no other treatment options are available. It is designed for those ineligible for clinical trials and requires a physician-led request.
Category: Clinical Trials
- How to get it
- Requests must be submitted by a licensed treating physician
- Target Patient Group
- Serious or life-threatening conditions
- Requestor Requirement
- Licensed treating physician
- Clinical Trial Status
- Must not interfere with ongoing trials
- Access to investigational drugs for serious or life-threatening conditions
- Available when no comparable or satisfactory alternative therapy exists
- Physician-initiated request process for qualifying patients
- Compliance with local laws and ethical guiding principles
Overview
Biogen Early Access Programs (EAPs) provide a potential pathway for patients diagnosed with serious or life-threatening diseases to gain access to investigational drugs for treatment outside of clinical trials. The program is intended for situations where no comparable or satisfactory alternative therapy options are available and the patient is ineligible to participate in ongoing clinical trials. Requests for access must be initiated and submitted by a licensed treating physician who confirms the patient's medical need. Biogen evaluates each request based on clinical data, ensuring that potential benefits outweigh risks and that providing the drug does not interfere with the integrity of clinical trials. The program operates in compliance with local laws and regulations to provide safe and ethical access to medicines in development.
Access and Eligibility
- Investigational Drug Access: The program provides a pathway for patients with serious or life-threatening diseases to access investigational drugs outside of clinical trials.
- Unmet Medical Need: Access is considered when no comparable or satisfactory alternative therapy options are available for the patient's condition.
- Clinical Data Evaluation: Biogen evaluates requests based on clinical data to ensure the potential benefits of the treatment outweigh the potential risks.
Program Principles and Process
- Ethical Compliance: Biogen provides access in a safe, ethical, and just manner in compliance with all applicable local laws and regulations.
- System Burden Reduction: The program is designed to minimize the burden on healthcare systems, providers, patients, and their families.
- Medical Information Support: Healthcare providers and patients can reach out to the Biogen Medical Information Team for questions regarding the program.
Use cases
- Physicians request investigational drugs for patients with life-threatening conditions who have exhausted all approved treatment options.
- Patients ineligible for clinical trials gain access to medicines in development when no satisfactory alternative therapy exists.
- Healthcare providers coordinate with Biogen to provide ethical access to investigational treatments while maintaining clinical trial integrity.
Specifications
- How to get it
- Requests must be submitted by a licensed treating physician
- Target Patient Group
- Serious or life-threatening conditions
- Requestor Requirement
- Licensed treating physician
- Clinical Trial Status
- Must not interfere with ongoing trials
How it works
- Physician Assessment: A licensed treating physician determines that a patient with a serious condition has exhausted all other treatment options and is ineligible for clinical trials.
- Request Submission: The physician submits a formal request for the investigational drug to Biogen on behalf of the patient.
- Biogen Evaluation: Biogen evaluates the request based on clinical data, drug supply, and the impact on existing clinical development programs.
- Access Provision: If approved and allowed by local laws, the investigational drug is provided for treatment outside of the clinical trial setting.
FAQ
What is the Biogen Early Access Program?
Early access is a pathway for patients with serious or life-threatening conditions to gain access to investigational drugs outside of clinical trials when no comparable alternative therapy is available.
Who is eligible for early access?
A patient must have a serious or life-threatening condition, have no satisfactory alternative therapy, be ineligible for clinical trials, and the potential benefits must outweigh the risks.
How can a patient request access?
All requests must be initiated and submitted by a licensed treating physician on behalf of the patient.
Added by AntSpace from public sources (biogen.com).